MetLife Investment Management’s Avanos Medical AVNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $364K | Hold |
26,010
| – | – | ﹤0.01% | 1909 |
|
|
2025
Q4 | $292K | Sell |
26,010
-1,171
| -4% | -$13.4K | ﹤0.01% | 2085 |
|
|
2025
Q3 | $314K | Hold |
27,181
| – | – | ﹤0.01% | 2054 |
|
|
2025
Q2 | $333K | Hold |
27,181
| – | – | ﹤0.01% | 1890 |
|
|
2025
Q1 | $390K | Sell |
27,181
-504
| -2% | -$7.87K | ﹤0.01% | 1845 |
|
|
2024
Q4 | $441K | Hold |
27,685
| – | – | ﹤0.01% | 1873 |
|
|
2024
Q3 | $665K | Hold |
27,685
| – | – | ﹤0.01% | 1624 |
|
|
2024
Q2 | $551K | Buy |
27,685
+2,471
| +10% | +$48.1K | ﹤0.01% | 1675 |
|
|
2024
Q1 | $502K | Hold |
25,214
| – | – | ﹤0.01% | 1676 |
|
|
2023
Q4 | $566K | Hold |
25,214
| – | – | ﹤0.01% | 1614 |
|
|
2023
Q3 | $510K | Hold |
25,214
| – | – | ﹤0.01% | 1621 |
|
|
2023
Q2 | $644K | Hold |
25,214
| – | – | ﹤0.01% | 1528 |
|
|
2023
Q1 | $750K | Hold |
25,214
| – | – | 0.01% | 1389 |
|
|
2022
Q4 | $682K | Hold |
25,214
| – | – | 0.01% | 1440 |
|
|
2022
Q3 | $549K | Hold |
25,214
| – | – | ﹤0.01% | 1572 |
|
|
2022
Q2 | $689K | Sell |
25,214
-2,428
| -9% | -$69.8K | 0.01% | 1444 |
|
|
2022
Q1 | $926K | Buy |
27,642
+9,311
| +51% | +$300K | 0.01% | 1385 |
|
|
2021
Q4 | $636K | Hold |
18,331
| – | – | 0.01% | 1380 |
|
|
2021
Q3 | $572K | Hold |
18,331
| – | – | 0.01% | 1453 |
|
|
2021
Q2 | $667K | Sell |
18,331
-24,775
| -57% | -$1.02M | 0.01% | 1405 |
|
|
2021
Q1 | $1.89M | Sell |
43,106
-3,966
| -8% | -$186K | 0.02% | 889 |
|
|
2020
Q4 | $2.16M | Sell |
47,072
-1,211
| -3% | -$50.4K | 0.02% | 788 |
|
|
2020
Q3 | $1.6M | Sell |
48,283
-975
| -2% | -$31.2K | 0.02% | 817 |
|
|
2020
Q2 | $1.45M | Buy |
49,258
+849
| +2% | +$24.6K | 0.02% | 870 |
|
|
2020
Q1 | $1.3M | Hold |
48,409
| – | – | 0.02% | 794 |
|
|
2019
Q4 | $1.63M | Sell |
48,409
-238
| -0.5% | -$8.62K | 0.02% | 887 |
|
|
2019
Q3 | $1.82M | Sell |
48,647
-395
| -0.8% | -$15.1K | 0.02% | 823 |
|
|
2019
Q2 | $2.14M | Sell |
49,042
-717
| -1% | -$30.7K | 0.02% | 785 |
|
|
2019
Q1 | $2.12M | Buy |
49,759
+6
| +0% | +$269 | 0.02% | 797 |
|
|
2018
Q4 | $2.23M | Sell |
49,753
-27
| -0.1% | -$1.42K | 0.03% | 710 |
|
|
2018
Q3 | $3.41M | Sell |
49,780
-668
| -1% | -$43K | 0.03% | 580 |
|
|
2018
Q2 | $2.89M | Buy |
50,448
+270
| +0.5% | +$14.3K | 0.03% | 636 |
|
|
2018
Q1 | $2.31M | Sell |
50,178
-325
| -0.6% | -$15.4K | 0.03% | 725 |
|
|
2017
Q4 | $2.33M | Buy |
+50,503
| New | +$2.32M | 0.03% | 747 |
|
Other funds holding AVNS
AC
VCM
VPM
MetLife Investment Management's AVNS Position: Q1 2026 in Review
MetLife Investment Management held its Avanos Medical (AVNS) position steady in Q1 2026 at 26,010 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #1909.
MetLife Investment Management first reported a position in AVNS in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.41M in Q3 2018. 257 funds tracked by Wall St. Rank hold AVNS as of Q1 2026.
- MetLife Investment Management held 26,010 shares of Avanos Medical worth $364K as of Q1 2026.
- MetLife Investment Management left its Avanos Medical share count unchanged in Q1 2026.
- Avanos Medical made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1909 holding.
- MetLife Investment Management first reported a position in Avanos Medical in Q4 2017 and has held it in 34 quarters since.
- MetLife Investment Management's Avanos Medical position peaked at $3.41M in Q3 2018.
- 257 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2026.
Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.